老虎證券

BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial

Reuters
02/03
BRIEF-Pfizer’S Ultra-Long-Acting Injectable Glp-1 RA Shows Weight Loss Results In Phase 2B Trial

Feb 3 (Reuters) - Pfizer Inc PFE.N:

  • PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIAL

  • PFIZER’S ULTRA-LONG-ACTING INJECTABLE GLP-1 RA SHOWS ROBUST AND CONTINUED WEIGHT LOSS WITH MONTHLY DOSING IN PHASE 2B TRIAL

  • PFIZER - STUDY SHOWS 12.3% WEIGHT LOSS AT WEEK 28

  • PFIZER - 10 PHASE 3 TRIALS WITH PF’3944 EXPECTED IN 2026

  • PFIZER - STUDY MET PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT WEIGHT REDUCTION AT 28 WEEKS WITH A COMPETITIVE TOLERABILITY PROFILE

  • PFIZER - PF’3944 MAINTAINS FAVORABLE SAFETY PROFILE THROUGH WEEK 28

  • PFIZER - PLANNING AN EXPANSIVE OBESITY DEVELOPMENT PROGRAM ACROSS ITS PIPELINE, WITH PLANS TO ADVANCE 20+ TRIALS IN 2026

  • PFIZER: ACROSS ARMS 1 AND 3, FIVE TOTAL PARTICIPANTS DISCONTINUED FROM TREATMENT DUE TO ADVERSE EVENTS IN WEEKLY PHASE

  • PFIZER: ACROSS ARMS 1 AND 3 FIVE TOTAL PARTICIPANTS DISCONTINUED FROM TREATMENT DUE TO AES IN MONTHLY PHASE

Source text: ID:nBw15qHG9a

Further company coverage: PFE.N

((Reuters.Briefs@thomsonreuters.com;))

應版權方要求，你需要登入查看該內容

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10